Avalo Therapeutics Holds 2025 Annual Meeting

Avalo Therapeutics ( (AVTX) ) just unveiled an update.

Avalo Therapeutics held its 2025 Annual Meeting on June 17, 2025, where stockholders voted on several key proposals. The meeting saw a high participation rate with approximately 90% of shares present or represented by proxy. During the meeting, eight nominees were elected to the Board, a ‘Say-on-Pay’ resolution was approved, and Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (AVTX) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Avalo Therapeutics stock, see the AVTX Stock Forecast page.

Spark’s Take on AVTX Stock

According to Spark, TipRanks’ AI Analyst, AVTX is a Neutral.

The overall score reflects significant financial instability and poor valuation metrics, partially offset by promising corporate events. Technical analysis suggests mixed trends, adding uncertainty to the stock’s outlook.

To see Spark’s full report on AVTX stock, click here.

More about Avalo Therapeutics

Average Trading Volume: 71,233

Technical Sentiment Signal: Strong Sell

Current Market Cap: $49.92M

For an in-depth examination of AVTX stock, go to TipRanks’ Overview page.